Showing 3861-3870 of 7113 results for "".
- Merz’s Xeomin Taps Teyana Taylor as Brand Partnerhttps://practicaldermatology.com/news/merzs-xeomin-taps-teyana-taylor-as-brand-partner/2461412/Teyana Taylor is the latest brand partner for Merz’z Xeomin (incobotulinumtoxinA). The U.S. partnership is a continuation of the ‘Beauty on Your Terms’ campaign for Xeomin, an FDA-approved double filtered anti-wrinkle injection to temporarily improve the appearanc
- EWG: FDA Must Ban Oxybenzone in Sunscreen Now!https://practicaldermatology.com/news/ewg-fda-must-ban-oxybenzone-in-sunscreen-now/2461405/The U.S. Food and Drug Administration (FDA) should ban oxybenzone in sunscreens, according to researchers at the Environmental Working Group (EWG). For decades, sunscreen makers have used oxybenzone in their products, despite concerns about its health harms. In 2021, the FDA t
- Nevisense Improves Dermatologist’s Decision-making Beyond Dermoscopyhttps://practicaldermatology.com/news/nevisense-improves-dermatologists-decision-making-beyond-dermoscopy/2461403/SciBase’s Nevisense test provides benefit over standard of care visual and dermoscopic evaluation for biopsy decisions, according to a study in Melano
- EltaMD Honored in Fast Company Magazine’s 2022 “Brands That Matter” Listhttps://practicaldermatology.com/news/eltamd-honored-in-fast-company-magazines-2022-brands-that-matter-list/2461402/EltaMD has been named to Fast Company’s “Brands that Matter” list for its memorable campaign to increase awareness of skin cancer and how to prevent it. The list honors companies and nonprofits that have had an undeniable impact on business and culture. Skin
- Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosishttps://practicaldermatology.com/news/seborrheic-dermatitis-survey-shows-burdensome-and-lengthy-path-to-diagnosis/2461396/Arcutis Biotherapeutics, Inc., shared results of a nationwide survey of adults with seborrheic dermatitis and the health care providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease. The online survey was conducted by T
- Aesthetics Biomedical's Vivace Ultra Wins FDA Clearancehttps://practicaldermatology.com/news/aesthetics-biomedicals-vivace-ultra/2461390/The FDA has given the nod to Aesthetics Biomedical Inc.’s Vivace Ultra for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. An innovative reimagination and technical upgrade of the legacy Vivace Microneedle RF device, the Vivace Ultra comb
- Galderma's Alastin Rolls Out Pigment-Reducing A-LUMINATE BRIGHTENING SERUMhttps://practicaldermatology.com/news/galdermas-alastin-rolls-out-pigment-reducing-a-luminate-brightening-serum/2461386/Galderma’s ALASTIN Skincare is rolling out A-LUMINATE BRIGHTENING SERUM to help reduce the appearance of surface pigmentation without any harsh, irritating ingredients. A-LUMINATE BRIGHTENING SERUM contains a multifaceted blend of peptides, antioxidants, and targeted in
- Dr. Ida Orengo Named Chair of Department of Dermatology at Baylor College of Medicinehttps://practicaldermatology.com/news/dr-ida-orengo-named-chair-of-department-of-dermatology-at-baylor-college-of-medicine/2461384/Dr. Ida Orengo has been named chair of the Department of Dermatology at Baylor College of Medicine by the College’s Board of Trustees. Her appointment is effective Oct. 17. Dr. Ore
- Castle Bioscience’s DecisionDx-SCC Test Boosts Mohs Surgeons' Confidencehttps://practicaldermatology.com/news/castle-biosciences-decisiondx-scc-test-boosts-mohs-surgeons-confidence/2461382/Castle Bioscience’s DecisionDx-SCC test results can assist Mohs surgeons in making risk-aligned management plans and increase confidence in their treatment decisions, according to data presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. DecisionD
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i